Target Workspace

NaV1.7 / SCN9A

Voltage-gated sodium channel·Moderate-HighImproving·Review recommended·TSTranslational Science· Updated 3 days ago

Overview Evidence Patient Segments Risks Options Decision Brief Sources

Strategic options

Decision matrix comparing reasonable actions on the same evidence framework.

AI recommendation rationaleAI-assisted

Recommended for review: watch and reassess. Strong genetics, but druggability and clinical translation remain unresolved. Final decision sits with Portfolio Strategy.

Option	Capital	Time to readout	Strategic fit	Dependencies	Triggers	Recommendation
Build internal program now	High	18-24 mo	High (synergy with existing peripheral pain platform)	Selective chemistry strategy in place POC biomarker plan	Failure of internal selectivity strategy	Alternative
Watch and reassess in 6 to 12 months	Low	<12 mo (for new external evidence)	Moderate (preserves optionality)	Active monitoring of public pipeline and literature	Competitor reports a successful POC with selective design New genetics expands or narrows the indication landscape	Recommended for review
License or partner	Moderate	Variable; depends on asset stage	Moderate (gains chemistry; loses control)	Identified target asset Acceptable IP and deal terms	Asset becomes available Acquirer interest from competitor	Alternative

Rationale

Genetic validation is high. Chemistry challenge is the central risk. New GWAS evidence improves but does not resolve conviction. One or two near-term external readouts could shift the recommendation materially. Watch and reassess preserves optionality with low cost.

Decision workflow

Current recommendationWatch and reassess

Review ownerPortfolio Strategy

Next review6 months or trigger-based

StatusReady for committee review

Generate decision brief

Decision history

Evidence update added
GWAS card · 3 days ago
Risk review completed
Translational Science · 1 wk ago
Feasibility review completed
Clinical Ops · 2 wks ago
Recommendation generated
Portfolio Strategy · 2 wks ago